Adrebrelimab is a high-affinity humanized monoclonal antibody against PD-L1 that has demonstrated efficacy and safety in advanced esophageal squamous cell carcinoma (ESCC) (43), extensive SCLC (SCLC) (44), and resectable non-small cell lung cancer (NSCLC) (45). The gene discussed is CD274; the disease is small cell lung carcinoma.